News >

FDA Grants Pertuzumab Priority Review for HER2+ Early Breast Cancer

Jason M. Broderick @jasoncology
Published: Friday, Sep 29, 2017

Dr. Sandra Horning

Sandra Horning, MD
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

“We are pleased to receive priority review for the Perjeta-based regimen for the adjuvant treatment of HER2-positive early breast cancer,” Sandra Horning, MD, chief medical officer and head of Global Product Development, Genentech, said in a statement. “The goal of treating breast cancer early is to provide people with the best chance for a cure. Despite advances in the treatment of this disease, many people treated with the current standard of care still see their cancer return.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication